Table 2.
Benefits of the screening programs examined in this study with various eligibility criteria.
| Strategy (age-start_stop_pack-years) | Cohort screened (%) | # Screening LDCT per 100ka | Screening detected Lung cancer cases per 100ka | Lung cancer mortality reduction among total population (%) | Lung cancer mortality reduction among current smokers | Lung cancer mortality reduction among former smokers | Life-years gained per 100ka |
| Age_45_72_PY20 | 34.3 | 552 102 | 813 | 13.3 | 18.1 | 10.9 | 2246 |
| Age_45_72_PY30 | 24.1 | 388 513 | 727 | 10.5 | 14.6 | 8.0 | 1752 |
| Age_45_77_PY20 | 34.3 | 585 621 | 959 | 14.3 | 19.2 | 12.1 | 2359 |
| Age_45_77_PY30 | 24.4 | 412 719 | 860 | 11.3 | 15.6 | 8.9 | 1841 |
| Age_50_72_PY20 | 30.9 | 420 056 | 705 | 11.3 | 15.0 | 9.6 | 1806 |
| Age_50_72_PY30 | 22.0 | 306 173 | 635 | 9.0 | 12.2 | 7.4 | 1414 |
| Age_50_77_PY20 | 30.9 | 453 543 | 850 | 12.3 | 16.2 | 10.9 | 1919 |
| Age_50_77_PY30 | 22.3 | 330 343 | 768 | 9.8 | 13.1 | 8.2 | 1498 |
| Age_55_72_PY20 | 26.5 | 298 133 | 575 | 8.8 | 11.4 | 8.1 | 1361 |
| Age_55_72_PY30 | 19.1 | 215 902 | 520 | 6.9 | 9.0 | 6.3 | 1042 |
| Age_55_77_PY20 | 26.5 | 331 597 | 718 | 9.9 | 12.5 | 9.3 | 1474 |
| Age_55_77_PY30 (CMS) | 19.4 | 240 035 | 652 | 7.7 | 9.8 | 7.2 | 1128 |
LDCT. low-dose computed tomography.
aNumbers are per 100 000 individuals (100k) at age 40 followed to death.